ALNY

Alnylam Pharmaceuticals, Inc. Press Releases

$124.81
*  
0.07
0.06%
Get ALNY Alerts
*Delayed - data as of May 22, 2015  -  Find a broker to begin trading ALNY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for Revusiran, an Investigational RNAi Therapeutic for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
5/20/2015 7:00:00 AM - Business Wire
▲6.38 % Price Change since this news event. The Volume Ratio is 1.73.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Walmart reports Q1 FY 16 EPS of $1.03
5/19/2015 7:02:00 AM - Business Wire


Alnylam Files Clinical Trial Application (CTA) for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
5/17/2015 10:30:00 AM - Business Wire
▲3.23 % Price Change since this news event. The Volume Ratio is 1.04.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day
























iBio Adds Anthrax Antibodies to Product Pipeline
2/25/2015 8:31:00 AM - Market Wire